Journal of Hepatology
Volume 49, Issue 2 , Pages 160-162 , August 2008

Tumor-specific marker genes for intrahepatic cholangiocarcinoma: Utility and mechanistic insight

References 

  1. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12:131–150
  2. Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873–875
  3. Maeda T, Kajiyama K, Adachi E, Takenaka K, Sugimachi K, Tsuneyoshi M. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol. 1996;9:901–909
  4. Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 2000;24:870–876
  5. Tsuji M, Kashihara T, Terada N, Mori H. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int. 1999;49:310–317
  6. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33:1175–1181
  7. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005;65:9603–9606
  8. Lodi C, Szabo E, Holczbauer A, Batmunkh E, Szı´jártó A, Kupcsulik P, et al. Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Mod Pathol. 2006;19:460–469
  9. Sobel G, Paska C, Szabo I, Kiss A, Kadar A, Schaff Z. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol. 2005;36:162–169
  10. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology. 2005;46:551–560
  11. Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, et al. Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int. 2005;55:63–69
  12. Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol. 2003;199:479–487
  13. Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169:877–888
  14. Alvaro D, Macarri G, Mancino MG, Marzioni M, Bragazzi M, Onori P, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med. 2007;147:451–459
  15. Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 2006;395:1–19
  16. Bruix J. Liver cancer: an evolving challenge reaching research maturity. Hepatology. 2008;47:1103–1104
  17. Gores GJ. The emergence of a new discipline, hepatobiliary oncology. Hepatology. 2008;47:365–366

☆ The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript. This work was supported by a grant from the NIH DK59427, the Mayo Clinic Clinical Investigator Program, and the Mayo Foundation.

☆☆ This work was supported by a grant from the NIH DK59427, the Mayo Clinic Clinical Investigator Program, and the Mayo Foundation.

PII: S0168-8278(08)00308-5

doi: 10.1016/j.jhep.2008.05.001

Journal of Hepatology
Volume 49, Issue 2 , Pages 160-162 , August 2008

Article Tools